Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927855 | 0.89 | REN (0.55) | TSHRRENPOLBTP53KDM4E | |
| SCHEMBL1015445 | 0.88 | TSHR (0.56) | TSHRRENPOLBTP53KDM4E | |
| SCHEMBL1047741 | 0.84 | REN (0.57) | TSHRRENPOLBTP53KDM4E | |
| SCHEMBL89401 | 0.84 | TSHR (0.71) | TSHRRENPOLBTP53THRB | |
| SCHEMBL6508989 | 0.83 | REN (0.56) | TSHRRENPOLBTP53KDM4E | |
| SCHEMBL55503 | 0.83 | REN (0.61) | TSHRRENPOLBTP53KDM4E | |
| SCHEMBL6721804 | 0.83 | REN (0.56) | TSHRRENPOLBTP53KDM4E | |
| SCHEMBL3065160 | 0.82 | REN (0.55) | TSHRRENPOLBTP53KDM4E | |
| SCHEMBL3074822 | 0.82 | POLB (0.45) | TSHRRENPOLBTP53MAPT | |
| SCHEMBL3065833 | 0.81 | TSHR (0.54) | TSHRRENPOLBTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | HEROLD PETER (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-1776359-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7799779-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| EP-1863803-B1 | SUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-1863802-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-7687495-B2 | Substituted piperidines | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1776359-A2 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| WO-2006103273-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006103275-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006005741-A2 | PIPERDINE DERIVATIVES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | REN, AGTR1, ACE | TSHR 824/4885REN 1/4885POLB 2956/4885 |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | TSHR 4539/4885REN 119/4885POLB 1719/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | TSHR 3211/4885REN 1/4885POLB 1031/4885 |
| US-20100029628-A1 | 2,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGT, AGTR1 | TSHR 3778/4885REN 1/4885POLB 2005/4885 |
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | TSHR 1153/4885REN 1/4885POLB 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.